Latest News | Dr Reddy's Launches Medication to Treat Chronic Constipation

New Delhi, Oct 28 (PTI) Dr Reddy's Laboratories on Monday said it has launched a first-in-class drug to treat chronic constipation.

The company will market the drug under the brand name BixiBat in India, the Hyderabad-based drug firm said in a statement.

Also Read | What Is Iron Beam Laser Interception System and How Does it Work? Israel’s New Air Defence System Set to Become Operation in 2025; Know All About It.

The launch follows approval granted to the company by the Central Drugs Standard Control Organisation (CDSCO), it added.

Dr Reddy's is the first company to receive approval for and launch such a drug (Elobixibat) in India.

Also Read | What Is Census? When Was the Last Census Conducted in India? As Government May Begin Population Survey in 2025, Here Are Key Details.

Elobixibat acts by inhibiting the reabsorption of bile acids from the ileum, thus increasing their concentration in the colonic lumen, leading to increased bowel movements due to stimulation of both colonic motility and fluid secretion irrespective of the transit speed.

"The launch of this first-in-class drug is the latest in our continued efforts to bring novel molecules to patients in India," Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said.

The clinical studies for BixiBat have demonstrated significantly better and promising outcomes, making it a breakthrough drug in the management of chronic constipation and enhancing the current standard of care for its treatment in India, he added.

Shares of the company ended 0.84 per cent up at Rs 1,313.80 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)